Copy to clipboard 
RTI recorded record revenues in 2Q19 due to strong performance of legacy spine products bolstered by the acquisition of the coflex stabilization device.
- Reiterated 2019 full year guidance of $325MM to $335MM in total revenue
- Growth attributable to performance of legacy spine franchise, amplified by the addition of coflex
- The integration of coflex is “approximately six months behind our initial plans,” per leadership, with onboarding and training taking longer than expected
- The company opened a new design center in Germany that leverages the talent and capabilities acquired from Paradigm Spine
- Legacy spine hardware had double-digit growth bolstered by continued success selling the Fortilink family of products, which reached 5,000 implants in the U.S.
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Spine | $32.7 | $22.6 | $10.1 | 44.6% |
| Orthobiologics | $39.0 | $37.8 | $1.2 | 3.2% |
| Total | $71.6 | $60.4 | $11.3 | 18.7% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Spine | $56.8 | $46.0 | $10.8 | 23.4% |
| Orthobiologics | $74.8 | $74.2 | $0.6 | 0.8% |
| Total | $131.6 | $120.3 | $11.3 | 9.4% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| US | $63.7 | $54.9 | $8.7 | 15.9% |
| Ex-US | $7.9 | $5.4 | $2.5 | 46.3% |
| Total | $71.6 | $60.4 | $11.3 | 18.7% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
| Amt | % of Sales | |
| Sales | $82.3 | |
| Cost of Sales | -$37.6 | 45.6% |
| Selling and Admin | -$39.0 | 47.4% |
| R & D | -$3.9 | 4.7% |
| Other | -$1.1 | 1.4% |
| Net Earnings | $0.7 | 0.9% |
Source: RTI Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
RTI recorded record revenues in 2Q19 due to strong performance of legacy spine products bolstered by the acquisition of the coflex stabilization device.
Reiterated 2019 full year guidance of $325MM to $335MM in total revenue
Growth attributable to performance of legacy spine franchise, amplified by the addition of coflex
...
RTI recorded record revenues in 2Q19 due to strong performance of legacy spine products bolstered by the acquisition of the coflex stabilization device.
- Reiterated 2019 full year guidance of $325MM to $335MM in total revenue
- Growth attributable to performance of legacy spine franchise, amplified by the addition of coflex
- The integration of coflex is “approximately six months behind our initial plans,” per leadership, with onboarding and training taking longer than expected
- The company opened a new design center in Germany that leverages the talent and capabilities acquired from Paradigm Spine
- Legacy spine hardware had double-digit growth bolstered by continued success selling the Fortilink family of products, which reached 5,000 implants in the U.S.
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Spine | $32.7 | $22.6 | $10.1 | 44.6% |
| Orthobiologics | $39.0 | $37.8 | $1.2 | 3.2% |
| Total | $71.6 | $60.4 | $11.3 | 18.7% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Spine | $56.8 | $46.0 | $10.8 | 23.4% |
| Orthobiologics | $74.8 | $74.2 | $0.6 | 0.8% |
| Total | $131.6 | $120.3 | $11.3 | 9.4% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| US | $63.7 | $54.9 | $8.7 | 15.9% |
| Ex-US | $7.9 | $5.4 | $2.5 | 46.3% |
| Total | $71.6 | $60.4 | $11.3 | 18.7% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
| Amt | % of Sales | |
| Sales | $82.3 | |
| Cost of Sales | -$37.6 | 45.6% |
| Selling and Admin | -$39.0 | 47.4% |
| R & D | -$3.9 | 4.7% |
| Other | -$1.1 | 1.4% |
| Net Earnings | $0.7 | 0.9% |
Source: RTI Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
